TCG Labs-Soleil
Kathy Miller is currently serving as the Chief Technology Officer and Co-Founder at Soleil Labs. With a background in therapeutic discovery, engineering, protein sciences, and production, Kathy has held various high-level positions in biopharmaceutical companies such as NGM Biopharmaceuticals, IGM Biosciences, Five Prime Therapeutics, Novartis, Merck Research Labs, and Genentech. Kathy obtained her Doctor of Philosophy (Ph.D.) in Molecular Genetics from The Ohio State University.
TCG Labs-Soleil
At TCG Labs-Soleil, we are establishing a pioneering venture-biotech model in collaboration with The Column Group. Our mission is to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases. Our approach integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub led by top-tier scientists (Soleil). This creates a powerful ecosystem forming and overseeing independent portfolio companies, each dedicated to single-asset biologic programs, guiding them from ideation to clinical proof of concept and positioning them for strategic partnerships and transformative medical advancements.